EX-5.1 2 mnlo-ex51_62.htm EX-5.1 mnlo-ex51_62.htm

Exhibit 5.1


140 Scott Drive

Menlo Park, California  94025

Tel: +1.650.328.4600  Fax: +1.650.463.2600





BrusselsNew York

Century CityOrange County




FrankfurtSan Diego

HamburgSan Francisco

Hong KongSeoul


LondonSilicon Valley

Los AngelesSingapore


MilanWashington, D.C.









February 28, 2019












Menlo Therapeutics Inc.

200 Cardinal Way, 2nd Floor
Redwood City, CA 94063



Registration Statement on Form S-8; 1,161,659 shares of Common Stock of Menlo Therapeutics Inc., par value $0.0001 per share


Ladies and Gentlemen:

We have acted as special counsel to Menlo Therapeutics Inc., a Delaware corporation (the “Company”), in connection with the registration by the Company of an aggregate of 1,161,659 shares of common stock of the Company, par value $0.0001 per share (the “Common Stock”), consisting of 929,327 shares of Common Stock (the “2018 Plan Shares”) issuable under the Menlo Therapeutics Inc. 2018 Omnibus Incentive Plan (the “2018 Plan”) and 232,332 shares of Common Stock (the “ESPP Shares” and, together with the 2018 Plan Shares, the “Shares”) issuable under the Menlo Therapeutics Inc. 2018 Employee Stock Purchase Plan (the “ESPP” and together with the 2018 Plan, the “Plans”).

The Shares are included in a registration statement on Form S–8 under the Securities Act of 1933, as amended (the “Act”), filed with the Securities and Exchange Commission (the “Commission”) on February 28, 2019 (the “Registration Statement”).  This opinion is being furnished in connection with the requirements of Item 601(b)(5) of Regulation S-K under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or the related prospectuses, other than as expressly stated herein with respect to the issue of the Shares.

As such counsel, we have examined such matters of fact and questions of law as we have considered appropriate for purposes of this letter.  With your consent, we have relied upon certificates and other assurances of officers of the Company and others as to factual matters without having independently verified such factual matters.  We are opining herein as to the General Corporation Law of the State of Delaware (the “DGCL”), and we express no opinion with respect to any other laws.

February 28, 2019

Page 2

Subject to the foregoing and the other matters set forth herein, it is our opinion that, as of the date hereof, when the Shares shall have been duly registered on the books of the transfer agent and registrar therefor in the name or on behalf of the purchasers and have been issued by the Company against payment therefor in the circumstances contemplated by the Plans, assuming in each case that the individual issuances, grants or awards under the Plans are duly authorized by all necessary corporate action and duly issued, granted or awarded and exercised in accordance with the requirements of law and the Plans (and the agreements and awards duly adopted thereunder and in accordance therewith), the issuance and sale of the Shares will have been duly authorized by all necessary corporate action of the Company, and the Shares will be validly issued, fully paid and nonassessable.  In rendering the foregoing opinion, we have assumed that the Company will comply with all applicable notice requirements regarding uncertificated shares provided in the DGCL.  

This opinion is for your benefit in connection with the Registration Statement and may be relied upon by you and by persons entitled to rely upon it pursuant to the applicable provisions of the Act.  We consent to your filing this opinion as an exhibit to the Registration Statement.  In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission thereunder.

Very truly yours,


/s/ Latham & Watkins LLP